title: [Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care].
abstract: OBJECTIVE
  The objective of this study was to estimate the continuous abstinence rates of varenicline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in 2 Primary Care (PC) External Support Units.
  
  
  METHODS
  Observational, multicentre, longitudinal study using a retrospective review of medical records.
  
  
  METHODS
  Six Primary Care Centres.
  
  
  METHODS
  Patients > 18 years, who began smoking cessation treatment between 1/01/2006 and 1/12/2008 with varenicline, bupropion or NRT were included in the analysis. CONTINUATION: Patient follow-up was conducted from time-baseline (day 1) and assessed at 6 and 12 months.
  
  
  METHODS
  comorbidities, effectiveness (continuous abstinence) and pharmacological tolerability.
  
  
  METHODS
  logistic regression models and Kaplan-Maier survival curves; P<.05.
  
  
  RESULTS
  A total of 957 smokers treated with NRT (53.0%), bupropion (25.1%) and varenicline (21.9%) were included in the analysis. Mean age: 47.6 (11.3) years; 58.6% men. 32.0% of smokers attended due to physical dependence. Average duration of smoking: 19.5 (6.7) years. At 6 months, 61.2% (95% CI: 54.6-67.8%) of participants in the varenicline group continuously abstained from smoking compared with 56.9% (95% CI: 50.6-63.2%) in the bupropion group, and 52.3% (95% CI: 48.0-56.6%) in the NRT group; P=.003. At 12 months, the rate of continuous abstinence was 57.4% (95% CI: 50.7-64.1%) in the varenicline group compared with 52.9% (95% CI: 46.6-59.2%) in the bupropion group and 47.1% (95% CI: 42.8-51.4%) in the NRT group; P=.002.
  
  
  CONCLUSIONS
  One year-follow up results suggest that varenicline is an appropriate alternative compared with bupropion and NRT on smoking cessation in the PC setting.
authors.affiliation: Dirección de Planificación, Badalona Serveis Assistencials S.A., Badalona, Barcelona, España. asicras@bsa.cat
authors.forename: Antoni
authors.initials: A
authors.lastname: Sicras Mainar
authors.forename: Ruth
authors.initials: R
authors.lastname: Navarro Artieda
authors.forename: Silvia
authors.initials: S
authors.lastname: Díaz Cerezo
authors.forename: Belén
authors.initials: B
authors.lastname: Martí Sánchez
authors.forename: Verónica
authors.initials: V
authors.lastname: Sanz De Burgoa
mesh_terms: D000293:Adolescent; D000328:Adult; D001552:Benzazepines / Q000009:adverse effects* / Q000627:therapeutic use; D016642:Bupropion / Q000009:adverse effects* / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000009:adverse effects* / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D011320:Primary Health Care; D011810:Quinoxalines / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D016540:Smoking Cessation / Q000379:methods*; D013375:Substance Withdrawal Syndrome / Q000453:epidemiology*; D000068580:Varenicline; D055815:Young Adult
chemical_list: D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline